Momelotinib improves symptom, spleen responses in symptomatic, anemic myelofibrosis

ByErin Post

ByMark Leiser

ByAaron T. Gerds, MD, MS

Aaron T. Gerds, MD, MS, spoke with Healio about the randomized phase 3 MOMENTUM study.

Researchers compared momelotinib (Sierra Oncology) — an oral ACVR1/ALK2 and JAK1/JAK2 inhibitor — with danazol for symptomatic and anemic patients with myelofibrosis who received prior treatment with a JAK inhibitor.

Investigators evaluated key symptom, anemia and spleen volume endpoints at 24 weeks, and the findings showed superiority with momelotinib.

In this video, Gerds provides an overview of the results — presented at European Hematology Association Congress — and highlights the potential implications of the findings.

Reference:

Verstovsek S, et al. Abstract S195. Presented at: European Hematology Association Congress; June 9-12, 2022; Vienna.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview

Disclosures: Sierra Oncology sponsored this study. Gerds reports consultant/advisory roles with CTI BioPharma, Imago BioSciences, MorphoSys, PharmaEssentia and Sierra Oncology.

Read more

Momelotinib improves symptom, spleen responses in symptomatic, anemic myelofibrosis

Reference:

Related Content